- Krita Pruthi [1]   ABSTRACT The impending expiry of Novo Nordisk’s patent portfolio on semaglutide, the active ingredient (“ API ”) in Ozempic and Wegovy, signals a decisive moment for India – the “Pharmacy of the Global South.” Semaglutide's global sales and therapeutic impact have been unprecedented, but patents, by their nature, are temporary monopolies. As India faces this “patent cliff”, questions of innovation, access, and global health equity come to the fore. Through Section 3(d)...

-       Aditya Sharma [1] & Keshav Bhardwaj [2]   ABSTRACT In a world where brands increasingly compete through sensory experiences, scent has emerged as the most evocative identifier of origin, yet it remains unrecognised legally. Despite its commercial power to trigger memory and brand association, trademark law continues to grapple with whether and how olfactory marks deserve protection. Comparing jurisprudence and commercial practice in these countries US, EU, UK, and UAE, this article...

-       Dr. Soumi Chatterje [1]     ABSTRACT This article dives into the big questions around generative AI and copyright law, especially when it comes to ‘authorship’ and ‘originality’. The Indian Copyright Act, 1957, was drafted long before AI came into existence and it presumes that every creative work is produced by a human. Today, advanced language models, image generators, and other AI systems are capable of producing text, code, and artistic works that closely resemble human-created...